RATIONALE: Questionnaires may help determine cancer patients' satisfaction with the quality of care they received in the hospital.

PURPOSE: Clinical trial to determine the effectiveness of questionnaires in assessing cancer patients' satisfaction with the quality of care they received in the hospital.

Condition	Treatment or Intervention
Quality of Life unspecified adult solid tumor, protocol specific	Procedure: quality-of-life assessment  Procedure: supportive care/therapy

Further Study Details: 

OBJECTIVES:

• Determine the scale structure, reliability, and validity of the QLQ-SAT32 patient satisfaction module in assessing the perception of the quality of care received in hospitals by patients with cancer.
• Determine the success of the QLQ-SAT32 patient satisfaction module when used with the QLQ-C30 core quality of life questionnaire, in terms of expanding on quality of life evaluation or providing information on treatment acceptability or preference of these patients.

OUTLINE: This is a descriptive, multicenter study. Patients are stratified according to age (18 to 49 vs 50 and over) and the cancer therapy received in hospital (surgery vs chemotherapy).

Patients in all strata receive the QLQ-SAT32 and QLQ-C30 questionnaires, a debriefing questionnaire, and the Oberst patient satisfaction visual analog scale prior to hospital discharge. Patients complete the materials at home within 7 days of discharge. A group of 100 patients have a repeat QLQ-SAT32 module mailed to them to be completed within 7 days of receipt of first questionnaire.

PROJECTED ACCRUAL: A total of 640-768 patients (160-192 per stratum) will be accrued for this study.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed cancer
• Hospitalization of at least 3 days
• No clinical evidence of brain metastases

PATIENT CHARACTERISTICS: Age

• 18 and over

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• No psychological, familial, sociological, or geographical condition that would preclude study
• Able to understand the language of the questionnaire
• Mentally fit to complete a questionnaire

PRIOR CONCURRENT THERAPY: Biologic therapy

• Not specified

Chemotherapy

• Prior chemotherapy allowed

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Prior surgery for cancer allowed

Other

• No concurrent participation in other quality of life studies that would preclude this study

Belgium
      Institut Jules Bordet, Brussels,  1000,  Belgium
France
      Centre Alexis Vautrin, Vandoeuvre-les-Nancy,  54511,  France
      Centre Paul Strauss, Strasbourg,  67085,  France
      Centre Regional Francois Baclesse, Caen,  14076,  France
      Institut Bergonie, Bordeaux,  33076,  France
      Institut Curie - Section Medicale, Paris,  75231,  France
      Institut Gustave Roussy, Villejuif,  F-94805,  France
Spain
      Hospital De Navarra, Pamplona,  31008,  Spain
Sweden
      Sahlgrenska University Hospital, GOTHENBURG,  S-413 45,  Sweden
      Uppsala University Hospital, Uppsala,  S-75183,  Sweden
United Kingdom
      Bristol Royal Infirmary, Bristol,  BS2 8HW,  United Kingdom

Study chairs or principal investigators

Anne Bredart,  Institut Curie - Section Medicale   

Study ID Numbers:  CDR0000256317; EORTC-15012
Record last reviewed:  July 2004
Last Updated:  October 13, 2004
Record first received:  September 6, 2002
ClinicalTrials.gov Identifier:  NCT00045019
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08